drugset / Trial / NCT02592421
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
Phase 3
Completed
30 enrolled
The University of Texas Health Science Center at San Antonio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.
Timeline
- Start
- 2015-10-23
- Primary completion
- 2018-10-01
- Completion
- 2019-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | — |